- Bonso Electronics International Inc. (BNSO): Important & Key Factors of Technology Stock
- What's the Analyst Recommendation for PhaseBio Pharmaceuticals Inc. (PHAS)?
- Alliance Resource Partners L.P. (ARLP): Important & Key Factors of Energy Stock
- AeroCentury Corp. (ACY) Plunged -11.39%, Can Traders Take Benefit?
- Pixelworks Inc. (PXLW): Important & Key Factors of Technology Stock
Can-Fite BioPharma Ltd. (CANF) share price plummeted -15.59% with the closing price of $1.82 on Friday. Can-Fite BioPharma Ltd. stock has an exchanging volume of 0.62 million shares, which is low, contrasted with its 3-months average volume of 838.48K shares. Its market capitalization has now reached to $28.04M.
Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020 on October 13, 2020 news published at Yahoo.
Can-Fite BioPharma Ltd. (CANF) reported that it will host a conference call with investors to provide an update on its Phase III psoriasis study and the positive interim data analysis and recommendations from the study’s Independent Data Monitoring Committee (IDMC). Dr. Michael Goldfarb, M.D., Dermatologist, Beaumont Hospital, Dearborn, Michigan, U.S., a key opinion leader in the treatment of psoriasis, will join the call which is scheduled to take place on Thursday, October 15, 2020 at 4:15 pm EDT.
Piclidenoson, Can-Fite’s lead drug candidate, offers several potential key benefits over psoriasis treatments currently on the market. As an oral pill taken twice daily, it offers ease of administration for patients who tend to prefer oral medications over injectables. As an oral drug, the Company believes Piclidenoson may be priced at a significantly lower cost than injectable biologics, and somewhat lower than the current oral medication on the market, Otezla®. A 2018 study on psoriasis patient preferences published in American Health & Drug Benefits showed the two most important considerations for choosing a psoriasis drug were route of administration and cost, with oral administration and lower cost being most preferred.
Piclidenoson has been dosed in over 1,500 patients with an excellent safety profile in clinical trials to date. In contrast, the biologics on the market approved to treat psoriasis have black box warnings. While psoriasis is a serious disease with quality of life implications for patients, it is not life threatening and therefore patients recognize that while they need a treatment that is effective, safety is also a very high priority.
With an estimated 125 million cases worldwide, psoriasis is considered an immune system problem that causes infections, stress and is a chronic disease with no cure. The market size for psoriasis is estimated to be $11.5 billion at the end of 2020.
CANF Past Trading Activity
The market tends to become urbane often, in any event, for prepared investors and traders. In any event, when a merchant got what he/she had expected, the market occasionally chooses to move the other way. This instability leads a few traders questioning and re-thinking their moves. This is the reason becoming acquainted with past price performance, just as both long and short time period, is significant. If we look the past performance, during the last one week, CANF price has rose by 1.06%. In the course of past three months sees the stock go down around -15.40%, while it has lost -0.60% over the past six months and -44.88% since the start of the year.
CANF Earning History
Earnings per share are the amount of profit that a company produces during a specific period, which is usually defined as a quarter (three calendar months) or a year. In recent quarter of (Sep 2020), the firm recorded a revenue of 716.2 million, which was higher than the gauge of 250k made by certain experts. For that equivalent quarter, Can-Fite BioPharma Ltd. posted -$1.05 earnings per share (EPS) which was underneath the consensus estimate of -$0.3 by -$0.75, which represents to a reduction by -250.00%.
CANF Price Performance
Let us presently take a gander at a portion of its probable help and opposition resistance. Late research on Can-Fite BioPharma Ltd. has seen its stock exchanging -38.34% underneath its three-month high price. A glance at the opposite side additionally observes stock exchanging +20.46% above its three-month low. A more extensive look sees CANF exchanging -63.25% beneath its 52-week high and 68.43% above from its 52-week low price.
CANF Instability & Beta Factor
The Volatility of a stock means that the stock’s drop or increase in the event that the more extensive market drops or rushes. A beta score higher than 1 implies that a stock is profoundly unpredictable while underneath 1 implies that the Volatility of a stock is low. If we look trading Volatility. Its 7-day Volatility is around 8.17%, while it has a month to month instability of 5.86%. The company has an ATR (Average True Range) of 0.13.